Two enzymes, two assay obligations
Neprilysin and aminopeptidase N are zinc-dependent peptidases with different substrate preferences and broader biological roles. Calling a molecule a dual inhibitor therefore creates two independent potency obligations. Activity against NEP does not mathematically imply activity against APN, and activity reported for a related scaffold does not transfer automatically to a new exact molecular graph.
A rigorous program starts with concentration-response measurements against purified human enzymes or qualified cellular systems. Vehicle controls, validated reference inhibitors, interference controls and orthogonal confirmation are necessary because aggregation, fluorescence interference or nonspecific metal binding can mimic inhibition. Each result must remain attached to the exact stereochemistry, salt form and analytical identity of the tested material.
The intersection is the real design space
Single-target lists are not enough for a dual mechanism. Constructively, the first candidate universe is the intersection of compounds with evidence against NEP and compounds with evidence against APN. Even that intersection is only a discovery index: records can arise from different assays, concentrations, preparations or confidence levels and may not demonstrate balanced activity in one controlled experiment.
The next filter is selectivity. Both enzymes process substrates beyond enkephalins, and related metallopeptidases can create off-target liabilities. A useful profile therefore includes potency ratios across an enzyme panel, time dependence, reversibility where relevant and evidence that the intended activity survives the actual biological matrix. The dual label is earned by the complete measurement tuple.
Exposure connects chemistry to biology
An active compound in a biochemical well may never reach the relevant tissue at an adequate unbound concentration. Solubility, permeability, protein binding, metabolic stability and clearance determine whether an in-vitro result can influence an in-vivo system. For peptide-preservation research, location matters because peripheral and central compartments need not produce the same response.
Target engagement must also be distinguished from a downstream outcome. Reduced enzyme activity, altered peptide concentration and a reported subjective or functional effect sit at different levels of the causal chain. Human STR-324 research illustrates why these layers should remain separate: a program can be scientifically informative even when pharmacodynamic or clinical signals are not straightforward.
A constructive certificate for C1
The NOVA-4 compiler represents C1 qualification as a conjunction rather than a narrative. Exact identity, NEP activity, APN activity, orthogonal confirmation, selectivity, exposure, target engagement and combination compatibility must each resolve. One failing or absent predicate prevents the mechanism from being presented as a finished-product fact.
This representation is valuable beyond one molecule. It allows a laboratory to replace a design candidate with measured data without rewriting the surrounding logic. Every new observation changes a named proof object, the replay hash changes, and the public explanation can be regenerated from the newly certified state. The result is a traceable research system rather than a static claim.